

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2023

Talis Biomedical Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-40047
(Commission File Number)

46-3122255
(IRS Employer
Identification No.)

1100 Island Drive
Suite 101
Redwood City, California
(Address of Principal Executive Offices)

94065
(Zip Code)

Registrant's Telephone Number, Including Area Code: (650) 433-3000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	TLIS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2023, Talis Biomedical Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On August 10, 2023, the Company posted an updated investor presentation to its website at <https://investors.talisbio.com>. A copy of the investor presentation is attached hereto as Exhibit 99.2.

The information contained under this Item 7.01, including Exhibit 99.2 attached, hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act or under the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Exhibit Title
99.1	Press release dated August 10, 2023.
99.2	Corporate Presentation dated August 2023.
104	Cover Page Interactive Data File (Embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TALIS BIOMEDICAL CORPORATION

Date: August 10, 2023

By: /s/ Rebecca L. Markovich
Rebecca L. Markovich
Interim Chief Financial Officer

Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

REDWOOD CITY, Calif. – August 10, 2023 – Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Recent Business Highlights

- Initiated clinical study to support COVID-19 510(k) submission for clearance of the Talis One[®] system
- Presented positive data at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) annual meeting differentiating the planned Talis One test menu
 - o Development-stage chlamydia, gonorrhea and trichomonas (CT/NG/TV) assay demonstrated clinical performance comparable to widely used on-market molecular tests in less than 30 minutes
 - o Established ability to effectively lyse multiple *Candida* species in under four minutes on the Talis One system, positioning the Company to develop a point-of-care vaginal infection panel
- Appointed diagnostic industry veterans, Dr. Heiner Dreismann to the Talis Biomedical Board of Directors and Dr. Andrew Lukowiak as president and chief scientific officer
- Delivered 53% improvement in year-to-date net cash used in operating activities year-over-year to support cash runway into 2025

“During the second quarter, we made important progress across our strategic priorities to develop and deliver a targeted menu of infectious disease tests that women’s and sexual health providers are seeking at the point of care,” said Rob Kelley, chief executive officer of Talis Biomedical. “With the data we are generating, our focused execution and healthy cash position, it is our plan to secure regulatory clearance for three test panels by the end of 2025. We are excited for the opportunity to capture this large and growing market and to make a meaningful impact on the delivery of timely and accurate patient care.”

Second Quarter 2023 Financial Results

Revenue was \$0.6 million for the second quarter of 2023, which includes \$0.5 million of NIH grant revenue. Revenue was \$0.6 million for the same period in 2022.

Operating expenses were \$17.0 million in the second quarter of 2023, compared to \$27.8 million for the same period in 2022. The decrease was primarily driven by lower investments in raw card inventory and manufacturing as well as the realization of benefits from the spending reduction measures implemented during 2022.

Net loss was \$15.0 million for the second quarter of 2023, compared to \$27.0 million for the same period in 2022.

Cash and Liquidity

Unrestricted cash and cash equivalents as of June 30, 2023, were \$98.2 million.

Net cash used in operating activities for the six months ended June 30, 2023 was \$30.7 million, as compared to \$65.8 million in the same period of 2022. This decrease was primarily driven by lower headcount costs from the Company’s spending reduction program as well as declines in payments for raw card inventory and manufacturing investments.

To support long-term financial objectives, the Company recently reduced its Redwood City, California office and lab space by two-thirds. The Company expects approximately \$9 million of cash savings over the life of the lease.

About the Talis One System

The Talis One system is a compact, sample-to-answer molecular testing platform designed to enable rapid, highly accurate point-of care infectious disease testing in non-laboratory settings. The Talis One test cartridge is a fully self-contained, closed device that includes all the necessary reagents to perform a Talis One test. When loaded into the Talis One instrument, each cartridge fully automates sample lysis, nucleic acid extraction and purification, isothermal amplification, and target detection. The Talis One test system is not authorized, cleared, or approved by the FDA and is not available for sale.

About Talis Biomedical

Talis Biomedical is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The Company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing. For more information, visit talisbio.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “would,” “should,” “believe,” “expect,” “anticipate,” “could,” “estimate,” “continue,” “predict,” “potential,” “forecast,” “project,” “plan,” “intend” or similar expressions, or other words that convey uncertainty of future events or outcomes can be used to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our plans to advance our pipeline, including the plans to develop Talis One assays in the women’s and sexual health markets; the size and potential of our opportunity in the women’s and sexual health markets; our ability to capitalize on any competitive advantages; our ability to position the Company to provide durable value to our shareholders; the benefits of our regulatory strategy; our future revenue growth and profit margins; and our ability to lower our cash burn, extend operations and extend our cash runway. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties associated with development and regulatory approval, the impact to our business from global and regional economic conditions, including as a result of government policies, war, terrorism, natural disasters, public health issues and inflationary pressures and any related impact on our ability to develop our pipeline products, our ability to achieve or sustain profitability, our ability to launch and gain market acceptance for our pipeline products and to accurately forecast and meet customer demand, our ability to compete successfully, our ability to enhance our product offerings, development and manufacturing, capacity constraints or delays in production of our products, product defects or failures. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Talis assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Contact

Media & Investors
Emily Faucette
efaucette@talisbio.com
415-595-9407

Talis Biomedical Corporation
Condensed Balance Sheets
(in thousands)

	June 30, 2023 (unaudited)	December 31, 2022
Assets		
Current assets:		
Cash and cash equivalents	\$ 98,200	\$ 130,191
Restricted cash	1,010	—
Accounts receivable, net	532	308
Prepaid expenses and other current assets	2,223	2,783
Total current assets	101,965	133,282
Property and equipment, net	3,539	3,312
Operating lease right-of-use-assets	16,030	30,920
Other long-term assets	1,542	1,776
Total assets	\$ 123,076	\$ 169,290
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 2,491	\$ 3,768
Accrued compensation	3,097	4,212
Accrued liabilities	938	989
Operating lease liabilities, current portion	2,736	3,703
Total current liabilities	9,262	12,672
Operating lease liabilities, long-term portion	17,648	29,879
Total liabilities	\$ 26,910	\$ 42,551
Stockholders' equity:		
Series 1 convertible preferred stock	3	3
Common Stock	—	—
Additional paid-in capital	606,982	604,690
Accumulated deficit	(510,819)	(477,954)
Total stockholders' equity	96,166	126,739
Total liabilities and stockholders' equity	\$ 123,076	\$ 169,290

Talis Biomedical Corporation
Condensed Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Revenue				
Grant revenue	\$ 533	\$ 70	\$ 1,614	\$ 944
Product revenue, net	48	502	185	2,815
Total revenue, net	581	572	1,799	3,759
Operating expenses:				
Cost of products sold	7	1,302	27	4,823
Research and development	10,555	17,365	24,351	38,068
Selling, general and administrative	6,410	9,178	12,809	21,108
Total operating expenses	16,972	27,845	37,187	63,999
Loss from operations	(16,391)	(27,273)	(35,388)	(60,240)
Other income, net	1,357	262	2,523	178
Net loss and comprehensive loss	\$ (15,034)	\$ (27,011)	\$ (32,865)	\$ (60,062)
Net loss per share, basic and diluted	\$ (8.27)	\$ (15.01)	\$ (18.11)	\$ (33.47)
Weighted average shares used in the calculation of net loss per share, basic and diluted	1,817,288	1,799,559	1,814,994	1,794,463



Decentralizing Women's and Sexual Health Testing

Talis Biomedical Corporate Presentation

August 2023



Disclaimer

This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Talis Biomedical (“Talis Bio,” “we,” “our”) has based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our plans to advance our pipeline, including our plans to develop Talis One assays in the women’s and sexual health markets; the size and potential of our opportunity in the women’s and sexual health markets; our ability to capitalize on any competitive advantages; our ability to position Talis Bio to provide durable value to our shareholders; our future revenue growth and profit margins; and our ability to lower our cash burn, extend operations and our cash runway. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties associated with development and regulatory approval, the impact to our business from global and regional economic conditions, including as a result of government policies, war, terrorism, natural disasters, public health issues and inflationary pressures and any related impact on our ability to develop our pipeline products, our ability to achieve or sustain profitability, our ability to launch and gain market acceptance for our pipeline products and to accurately forecast and meet customer demand, our ability to compete successfully and our ability to enhance our product offerings, development and manufacturing, capacity constraints or delays in production of our products, product defects or failures. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. *These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.* Any forward-looking statements that we make in this presentation speak only as of the date of this presentation, and Talis Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this presentation, except as required under applicable law.

This presentation also contains estimates and information concerning our industry and business, including estimated market size and projected growth rates of the markets in which Talis Bio participates. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Talis Bio has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, we cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of our future performance and the future performance of the industries in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Talis Bio.



Differentiated to Lead in Significant Untapped Market

Advancing health equity and outcomes by delivering accurate infectious disease testing in the moment of need, at the point of care



TALIS ONE® SYSTEM

Established innovative, high-performing diagnostic platform at the point of care (POC)



PROMISING PIPELINE OPPORTUNITY

Refocused product roadmap in growing women's and sexual health markets



OPERATIONAL OPTIMIZATION

Demonstrated scalable manufacturing capabilities with path to attractive margins



WELL-POSITIONED FOR COMMERCIALIZATION

Built strong commercial infrastructure



Women's/Sexual Health Providers Eager to Test at Point-of-Care



INHERENT CLINICAL ADVANTAGE

Accurate, immediate treatment reduces empirical prescribing, office visits and patients lost to follow-up



ECONOMIC BENEFIT

Shifts reimbursement to those providing care



COVID ACCELERATED POC PLATFORM ADOPTION

Created demand and channel for broader infectious disease testing at the point of care



Large and Growing Market Opportunity

Tailwinds will accelerate and sustain transition from lab-based testing to POC

40M

CT, NG + TV
tests performed
annually¹

24M

UTI, Vaginitis,
GBS + HSV
tests performed
annually²

\$3B

U.S. market
opportunity with
2022 W&SH testing
converted to POC²

- Incidence of STIs increasing and a growing public-health priority
- Patients are becoming engaged consumers, expecting convenience and immediacy
- Physicians want test results while patients are there
- Practices seeking new, profitable revenue streams
- Untapped opportunity with only 56% of sexually active females aged 16-24 screened for chlamydial infections³

The Talis One System is Designed to Win in POC Market



SAMPLE PREPARATION
Embedded Mechanical Lysis and
Nucleic Acid Purification



TARGET TURNAROUND
Results in <30 Minutes



EASE OF USE
Designed for CLIA-Waived
Settings



RELEVANT MENU
Actionable Women's and
Sexual Health Tests



LOW COST
Automated Manufacturing
Drives Down Cost

Talis One System

Technology Overview




Differentiated to Lead in Women's/Sexual Health Market



- ✓ POC sample-to-result in <30 minutes
- ✓ Demonstrated ease of use for untrained users¹
- ✓ Integrated DNA/RNA extraction, purification, detection and results management
- ✓ Proven to lyse difficult pathogens in <4 minutes²
- ✓ Multiple system interface capabilities or standalone function

Integrated Test Cartridge Enables Sample Prep, Menu Expansion

Self-Contained, Single Use Consumable Designed to Minimize Cross-Contamination



Instrument Designed for Ease-of-Use

- ✓ Designed for Untrained User
- ✓ Touchscreen Interface
- ✓ Cloud Connectivity
- ✓ Flexible Multiplexing



3 Simple Steps to Results in <30 Minutes



1 Label with patient ID:
Barcode or handwritten



2 Add specimen
to cartridge



3 Insert cartridge
into instrument



Results

Established Ability to Manufacture at Scale

Investment in automation provides advantages of quality, throughput and cost



>\$100M investment in automated manufacturing to deliver 1M tests/month at full scale



High speed assembly lines consistently produce cartridges



Ability to build instruments efficiently



Talis One System performing well in hands of study users



Three Tiers of Cartridge Manufacturing Lines Provide Flexibility and Stability as Business Scales

1. Manual



2. Semi Automated



3. Fully Automated



Business Use	<ul style="list-style-type: none"> • Research & Development 	<ul style="list-style-type: none"> • Clinical Studies/Early Commercialization 	<ul style="list-style-type: none"> • Full-Scale Commercialization
Capacity	<ul style="list-style-type: none"> • 300 cartridges/day 	<ul style="list-style-type: none"> • 2,000 cartridges/day¹ 	<ul style="list-style-type: none"> • 40,000 cartridges/day²
Benefit	<ul style="list-style-type: none"> • Flexibility to customize production for different assays in small batches 	<ul style="list-style-type: none"> • Additional volume with some customization and lower card to card variability 	<ul style="list-style-type: none"> • Volume to support commercial scale and attractive margins
Location	<ul style="list-style-type: none"> • Redwood Shores, CA (Talis) 	<ul style="list-style-type: none"> • Chicago, IL (Talis) 	<ul style="list-style-type: none"> • Phoenix, AZ (Contract Manufacturer)



¹ Assumes one 8-hour shift; ² Assumes operating all three lines simultaneously

Delivering Clinical and Economic Value to Physicians



Minimal capital costs and lower practice overhead with better informed diagnosis and treatment



Pricing below established CPT codes



Redirects reimbursement from central lab to providers



Not All POC Tests are Created Equal

Important Questions to Ask

- Does it include sample preparation to ensure lab-quality results?
- Can it generate a result in less than 30 minutes while the patient is in the office?
- Can an untrained user operate?
- Can it deliver multiplex panels with difficult to lyse organisms to meet customer needs?
- Can it be produced at scale for low cost?



SAMPLE PREPARATION

Embedded Mechanical Lysis and Nucleic Acid Purification



TARGET TURNAROUND

Results in <30 Minutes



EASE OF USE

Designed for CLIA-Waived Settings



RELEVANT MENU

Actionable Women's and Sexual Health Tests




LOW COST

Automated Manufacturing Drives Down Cost

Talis One Uniquely Positioned to Meet Key Customer Needs

Prioritizing Assay Development to Accelerate Market Entry

 <p>1</p>	 <p>2</p>	 <p>3</p>	 <p>4</p>
<p>Market Entrant</p>	<p>Volume Driver</p>	<p>Platform Differentiator</p>	<p>Platform Differentiator</p>
<p>Respiratory Panel Influenza A, Influenza B and SARS-CoV-2</p>	<p>CT/NG/TV Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis</p>	<p>HSV-1/2 Herpes Simplex Virus</p>	<p>Vaginal Panel Bacterial vaginosis, vulvovaginal candidiasis and trichomonas vaginalis</p>
<ul style="list-style-type: none"> ✓ Symptomatic patients ✓ Nasopharyngeal swab ✓ Ob/Gyn demand confirmed ✓ 510(k) pre submission complete 	<ul style="list-style-type: none"> ✓ Asymptomatic and Symptomatic patients ✓ Vaginal swab (self collected) ✓ Male urine ✓ 510(k) pre submission complete 	<ul style="list-style-type: none"> ✓ Symptomatic patients ✓ Anogenital lesion swab ✓ Early-stage planning 	<ul style="list-style-type: none"> ✓ Symptomatic patients ✓ Vaginal swab ✓ Feasibility studies underway ✓ Multi color detection and ability to lyse yeast on cartridge demonstrated

Roadmap for Menu Expansion



Talis Biomedical Wins Over Time



Large unmet need with shifting diagnostic testing from centralized labs to the point of care



Nascent and growing \$3B U.S. market opportunity addressing women's and sexual health testing



Talis One System designed to deliver accuracy, speed, and ease of use



High-value efficient product roadmap and clear path to attractive margins



Capitalized to execute strategy into 2025 with cash ending 2Q23 of \$98M

Thank you.